You asked for it and they listened!
Update on TMB-001: A Setback — But Not the End of the Story
There’s been an important update about TMB-001, a topical treatment being studied for people with congenital ichthyosis.
In a large Phase 3 clinical trial, TMB-001 did not perform better than the “vehicle” (the base cream without the active medication). Because of that, it did not meet the main goal needed for FDA approval.
That’s understandably disappointing news for our community.
But Here’s the Interesting Part
About 40% of participants improved during the study — including those using just the vehicle cream.
That means the base formula (the moisturizing cream itself) may have helped skin symptoms, even without the active drug ingredient.
Because of this, the company now plans to out-license the vehicle formula — essentially partnering with another company to make the base cream available more widely. It would likely be offered more like a specialty emollient product rather than an FDA-approved medication.
What This Means for Families
- There is still no FDA-approved treatment specifically for congenital ichthyosis.
- TMB-001 will not move forward as originally planned.
- However, the cream base used in the trial may become available and could offer symptom relief for some individuals. It is planned to become available in May on Amazon.
While this wasn’t the outcome many hoped for, it highlights something important: even in trials that don’t meet their main goal, we can still learn valuable information that may help the community.
We will continue to monitor updates and share information as it becomes available.
Read more here https://www.dermatologytimes.com/view/phase-3-setback-for-tmb-001-spurs-hopeful-out-licensing-of-vehicle-in-congenital-ichthyosis
